FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age
Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.
What's going on with polio, monkeypox, and COVID-19
The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention
Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.
What Omicron could mean for the pandemic
Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.
Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD
Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.
Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels
Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.
